Bloodletting device for polycythemia vera

Abstract

The invention discloses a bloodletting device for polycythemia vera. The device is characterized by comprising a bloodletting rubber tube, a fleam, a bloodletting container and an anti-blocking component, the anti-blocking component comprises conveying belts, a drive device and elastic extrusion components, and there are two conveying belts which are respectively located at two opposite sides of the bloodletting rubber tube; the elastic extrusion components arranged on the two conveying belts respectively correspond to each other and respectively push and extrude the two opposite sides of thebloodletting rubber tube, and the drive device can drive the elastic extrusion components to move in the blood flowing direction during the process of driving the conveying belts to rotate; the elastic extrusion components comprise rotary clamping bars, conflicting idler wheels and elastic pieces used for pushing the rotary clamping bars to rotate outward around the hinged portions with the conveying belts, and during the process of the elastic pieces releasing elastic potential energy, the elastic pieces can push the rotary clamping bars to make that the conflicting idler wheels always push and extrude the bloodletting rubber tube. The device can avoid that the blood flowing speed of the vein is slow so as to cause blood coagulation, and the bloodletting device is blocked.

Description

technical field [0001] The invention relates to the technical field of medical equipment, in particular to a bloodletting device for polycythemia vera. Background technique [0002] Polycythemia vera is a chronic myeloproliferative disease characterized by clonal disorder of pluripotent hematopoietic stem cells, mainly characterized by abnormal proliferation of erythroid cells. Due to this clonal disorder, normal morphological red blood cells, white blood cells, platelets and other Abnormal accumulation of progenitor cells in the absence of specific stimuli. This disease belongs to the category of myeloproliferative diseases. PV is often accompanied by abnormalities of more than one line of hematopoietic cells, its erythropoietin is reduced or normal, and endogenous erythropoietin colonies are not dependent on erythropoietin. The clinical features are slow onset, long course of disease, marked increase in red blood cells, increased blood volume, often accompanied by increa...

AI Technical Summary

Problems solved by technology

At present, when doctors treat patients with venous bloodletting, they generally use bloodletting bags (bloodletting bottles). There is an exhaust pipe. Due to the slow flow rate of venous blood, the above-mentioned bloodletting treatment mainly relies on the gravity of the blood itself to achieve bloodletting. The phenomenon of blockage affects the therapeutic effect

Images